Skip to main content
padlock icon - secure page this page is secure

In vitro Thrombolytic Potential of Actinoprotease from Marine Streptomyces violaceus VITYGM

Buy Article:

$68.00 + tax (Refund Policy)

Back ground: One of the most prevailing diseases that required effective drug as therapeutic purposes is cardiac related illness includes myocardial infarction Current scenario makes enzyme to raises their sector towards therapeutic as effective active component for such diseases.

Objectives: The main aim of the study was to isolate, screen, characterize and produce an extracellular thrombolytic protease from marine actinomycetes.

Methods: Marine actinomycete was isolated and characterized on the basis of morphological, biochemical, and molecular characterization. The primary screening for protease activity was done by casein hydrolysis method followed by radial caseinolytic assay. The actinoprotease was partially purified using ammonium sulfate precipitation technique followed by dialysis and Sephadex G-50 gel permeation chromatography.

Results: 16srDNA sequencing and BLAST search analysis of the sequence revealed close affiliation with Streptomyces genera and identified as Streptomyces violaceus VITYGM with 99% similarity. The specific activity of purified protease was found to be 1437 units/mg along with purification fold up to 1.5 times. The blood clot lysis activity was compared with the standard and found to lyse the blood clot with 97.43%. Till now very less evidences have been reported on actinoprotease. A single peak at retention time 0.9 min observed on high performance liquid chromatography (HPLC) confirmed the homogeneity of the preparation.

Conclusion: This is the first study to report on actinoprotease from Streptomyces violaceus VITYGM. This study emphasizes the potency of novel actinoproteases as active compound in drugs for the treatment of cardiovascular diseases.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Actinoproteases; Streptomyces violaceus; cardiovascular diseases; halophilic; purification; thromobolytics

Document Type: Research Article

Publication date: August 1, 2016

More about this publication?
  • Cardiovascular & Hematological Agents in Medicinal Chemistry aims to cover all the latest and outstanding developments in medicinal chemistry and rational drug design for the discovery of new Cardiovascular & Hematological Agents. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics in Cardiovascular & Hematological medicinal chemistry.

    Cardiovascular & Hematological Agents in Medicinal Chemistry
    is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments in cardiovascular & hematological drug discovery.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more